Eli Lilly Says to Present Evidence of Psoriasis Drug’s Potentia

Eli Lilly and Company (LLY) shares are lower 4% on Tuesday even after the pharmaceutical company said it will present positive results from the psoriasis drug ixekizumab clinical development program at the European Academy of Dermatology and Venereology Congress in Copenhagen, Denmark, in October.

“The data to be presented provide further evidence about ixekizumab’s potential, if approved, to help more people achieve clear skin and improve their quality of life,” senior VP of Lilly Bio-Medicines David Ricks said in a statement.

The company said it make 13 presentations with results on the investigational medicine’s efficacy, safety and patient-reported outcomes.

LLY Is trading in the upper half of the 52-week range between $60.58 and $92.85.

Companies: Eli Lilly and Company
Price: 83.22 Price Change: -3.35 Percent Change: -3.87